| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Aclaris Therapeutics, Inc. (ACRS) has 6 insiders with recent SEC Form 4 filings, including 1 buy and 0 sells. ACRS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 13.95M | $67.52M | - | |
| Other | 510.0K | $2.47M | - | |
| COO | 336.3K | $1.63M | - | |
| CEO | 274.8K | $1.33M | - | |
| Other | 18.7K | $90.5K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 7, 2015 | Cha Albert | Director | Buy | 13,352 | $11.00 | $146,872.00 | +4.6% |